Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 in Patients With High Grade Serous or Endometrioid Ovarian Cancer

NCT06618235 is registered in ClinicalTrials.gov with Theolytics Limited as lead sponsor.

NCT NCT06618235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06618235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 in Patients With High Grade Serous or Endometrioid Ovarian Cancer
Lead sponsor
Theolytics Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 24, 2024
Completion date
June 30, 2028
Enrollment
44 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer